Best practices in the use of damages experts in complex commercial arbitrations
In the article published in Managing and Resolving Commercial Disputes 2024, Andrew Tepperman offers insight on some common issues that arise when considering...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
CRA has a reputation for delivering rigorous analysis and expert testimony. Economic expertise is complemented by experience assisting life sciences companies with business and policy issues. This combination allows CRA to provide effective expert testimony and support.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comIn the article published in Managing and Resolving Commercial Disputes 2024, Andrew Tepperman offers insight on some common issues that arise when considering...
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings....
Andrew Tepperman is a panelist during the session titled “Damages issues in IP and life science disputes.” For more information on this event, click here.
An Interdisciplinary Program for In-House Counsel, Chief Officers, and Strategic Investors Hosted by Dechert and Co-sponsored by Charles River Associates Join...